These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38792322)

  • 1. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
    Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR
    Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R;
    Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
    Shimura M; Kitano S; Ogata N; Mitamura Y; Oh H; Ochi H; Ohsawa S; Hirakata A;
    Jpn J Ophthalmol; 2023 May; 67(3):264-279. PubMed ID: 36897413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy.
    Chen-Li G; Martinez-Archer R; Coghi A; Roca JA; Rodriguez FJ; Acaba-Berrocal L; Berrocal MH; Wu L
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
    Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
    Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections.
    Sawa M; Nakagawa N; Shunto T; Nishiyama I
    Am J Ophthalmol Case Rep; 2024 Mar; 33():101973. PubMed ID: 38116329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials.
    Li G; Zhu N; Ji A
    Medicine (Baltimore); 2023 Dec; 102(50):e36370. PubMed ID: 38115358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema.
    Takamura Y; Yamada Y; Morioka M; Gozawa M; Matsumura T; Inatani M
    Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):31. PubMed ID: 37856112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.
    Ishida S; Chen SJ; Murata T; Ogura Y; Ruamviboonsuk P; Sakamoto T; Fujita T; Kawano M; Ohsawa S; Abreu F; Haskova Z; Ives J; Silverman D; Yoon YH;
    Asia Pac J Ophthalmol (Phila); 2023 Sep-Oct 01; 12(5):451-459. PubMed ID: 37851562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
    Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
    Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema.
    Rush RB
    Clin Ophthalmol; 2023; 17():2397-2403. PubMed ID: 37605765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept.
    Ohara H; Harada Y; Hiyama T; Sadahide A; Minamoto A; Kiuchi Y
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374329
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema.
    Kusuhara S; Kishimoto-Kishi M; Matsumiya W; Miki A; Imai H; Nakamura M
    Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109622
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.
    Heier JS; Ho AC; Boyer DS; Csaky K; Vitti R; Perlee L; Chu KW; Asmus F; Leal S; Zeitz O; Cheng Y; Schmelter T; Brown DM
    J Vitreoretin Dis; 2023; 7(1):8-15. PubMed ID: 37008402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic retinopathy: Looking forward to 2030.
    Tan TE; Wong TY
    Front Endocrinol (Lausanne); 2022; 13():1077669. PubMed ID: 36699020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy.
    Tsai T; Alwees M; Asaad MA; Theile J; Kakkassery V; Dick HB; Schultz T; Joachim SC
    PLoS One; 2023; 18(1):e0280488. PubMed ID: 36662891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitreous protein networks around ANG2 and VEGF in proliferative diabetic retinopathy and the differential effects of aflibercept versus bevacizumab pre-treatment.
    Klaassen I; Avery P; Schlingemann RO; Steel DHW
    Sci Rep; 2022 Dec; 12(1):21062. PubMed ID: 36473885
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.